Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case Reports

Immune checkpoint inhibitors (ICIs) improve the outcomes of several types of cancer. However, they are also associated with various immune-related adverse events including myocarditis. ICI-induced myocarditis is a rare, potentially life-threatening adverse event. We herein report two cases of corticosteroid-refractory ICI-induced myocarditis. In both cases, additional immunosuppressive therapies, such as intravenous immunoglobulin and tacrolimus, successfully resolved myocarditis. Given the corticosteroid-refractory nature of these cases, we suggest that prompt addition of other immunosuppressive drugs to corticosteroid therapy should be considered in the treatment of ICI-induced myocarditis.

Authors

Institutions

Publication Details

Journal
Internal Medicine
Published
2024-09-03
DOI
https://doi.org/10.2169/internalmedicine.4162-24
Citations
3
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.85
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case Reports

Masaya Shimojima, Akihiro Nishiyama, Seiji Yano, Hiroshi Kotani et al.
3 citations
Internal Medicine
Cancer Immunotherapy and Biomarkers
0.85
article

Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case Reports

Masaya Shimojima, Akihiro Nishiyama, Seiji Yano, Hiroshi Kotani, Shinji Takeuchi, Hiroyuki Sakaguchi, Koushiro Ohtsubo, Chiaki Suzuki, Shigeki Nanjo, Kaname Yamashita, Shigeki Sato
article en
3 citations

Abstract

Immune checkpoint inhibitors (ICIs) improve the outcomes of several types of cancer. However, they are also associated with various immune-related adverse events including myocarditis. ICI-induced myocarditis is a rare, potentially life-threatening adverse event. We herein report two cases of corticosteroid-refractory ICI-induced myocarditis. In both cases, additional immunosuppressive therapies, such as intravenous immunoglobulin and tacrolimus, successfully resolved myocarditis. Given the corticosteroid-refractory nature of these cases, we suggest that prompt addition of other immunosuppressive drugs to corticosteroid therapy should be considered in the treatment of ICI-induced myocarditis.

Internal MedicineVol. 64(8)
Kanazawa University (JP), Kyoto University (JP), Kanazawa University Hospital (JP), Kanazawa Medical University Hospital (JP)
Good health and well-being
Openalex Percentile: Top 23%
Cancer Immunotherapy and Biomarkers
0.85
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case Reports — Masaya Shimojima, Akihiro Nishiyama, et al. · Internal Medicine (2024) | TGRS Research Map | TGRS